West Pharmaceutical Services (WPS) Q3 2026 Earnings Report
DE:WPS Q3 2026 EPS Results
- Actual EPS
- EUR 2.37
- Consensus EPS
- EUR 1.96
- Beat/Miss
- Beat by +EUR 0.41
- One Year Ago EPS
- EUR 1.75
DE:WPS Q3 2026 Revenue Results
- Actual Revenue
- EUR 780.32M
- Expected Revenue
- EUR 738.12M
- Beat/Miss
- Beat by +EUR 42.19M
- YoY Revenue Growth
- +8.72%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/29/2026
- Time
- Before Open
- Conference Call
- Thursday, October 29, 2026
West Pharmaceutical Services's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive: West exceeded Q3 revenue and earnings expectations, delivered broad-based organic growth, expanded margins significantly, raised full-year revenue and EPS guidance, and reported strong demand across HVP Components, GLP-1, biologics, and multiple geographies. The main challenges were the West Vantage decline, SmartDose 3.5 divestiture-related revenue effects, a 5% year-to-date free-cash-flow decrease, and expected moderation in HVP Delivery Device growth in Q4.
Management now anticipates full year revenue to be in the range of $3.41 billion-$3.42 billion, up from a prior range of $3.345 billion-$3.38 billion, with full year 2026 organic sales growth of 11.3%-11.6%, up from a prior range of 10%-11%; FX is expected to have a full year benefit of 120 basis points, while the SmartDose 3.5 divestiture negatively impacts reported growth by 160 basis points. Q4 revenues are expected at $820 million-$830 million, representing 6%-7% organic revenue growth and double-digit growth in HVP Components. Full year 2026 adjusted EPS is expected to be in the range of $9.38-$9.48, up from a prior range of $8.85-$9.05, representing growth of 29%-30% year over year, with full year operating margins expected to expand almost 300 basis points; projected full-year net interest income is $5 million, the tax rate is slightly lower than 18%, affiliate profits are roughly $18 million, and diluted shares outstanding are 71.4 million. Full year CapEx is expected to be between $215 million-$220 million, within the 6%-8% of revenue corridor, long-term price is 2%-3%, and new HVP finishing capacity is expected to come online in 18 to 24 months.
- Strong Third-Quarter Revenue and EarningsQ3 revenue was $874 million, up 8.7% on a reported basis and 11.9% organically, exceeding expectations. Adjusted EPS was $2.66, up 36% year over year and $0.47 above the midpoint of prior guidance.
- Proprietary Products Delivered Broad-Based GrowthThe Proprietary Products segment grew 16.6% organically. HVP Components revenue was $467 million, up 20% organically and representing 53% of total company revenue, driven by robust biologics growth, continued GLP-1 strength, and positive HVP product mix.
- HVP Components Growth Outside GLP-1 and Upgrade OpportunityHVP Components growth outside GLP-1s was in the high teens organically. The company added over 200 upgrade projects this year, with Annex 1 regulations driving upgrades in Europe and increasing upgrade activity in other geographies as regulatory frameworks raise containment-system requirements.
- GLP-1 Business Continued to AccelerateGLP-1 HVP revenue grew well into the [30s] organically and represented just under 12% of total quarterly revenue. Management said there were no one-time items in the quarter and described GLP-1 as a durable, longer-term growth driver supported by existing-product adoption, new therapeutic categories, next-generation molecules, generics, and expanded access.
- HVP Delivery Devices Posted 26% Organic GrowthHVP Delivery Device revenue was $99 million, flat on a reported basis and up 26% organically after excluding currency and the SmartDose 3.5 divestiture. Crystal Zenith and Administration Systems both contributed to growth.
- Standard Products Grew OrganicallyStandard Products revenue was $163 million, up 3% on an organic basis.
- Geographic Growth Was Strong Across All RegionsAsia Pacific revenue grew 42%, led by India and China and supported in part by the introduction of GLP-1s in both markets. The Americas grew 12%, while EMEA grew 6%. Asia Pacific represented 11% of total company revenue.
- Significant Gross and Operating Margin ExpansionTotal company gross margin was 39.7%, up 310 basis points year over year. Adjusted operating margin was 25.3%, up 420 basis points, driven primarily by gross-margin expansion, positive HVP mix, price contribution, plant performance, and SG&A leverage.
- Inflationary Pressures Were OffsetManagement stated that inflationary pressures on the cost base were offset through good plant performance and some cost recovery via pass-through.
- Positive Pricing ContributionPrice contributed just over 4 percentage points of growth in Q3. Management said the long-term planning assumption remains 2%-3% price growth, while pricing was ahead of that level this year.
- Capacity Expansion and Operational ImprovementsWest has been adding and training new shifts, optimizing its global network, and increasing capacity. At the Eschweiler site in Germany, increased automation is helping expand output and support network optimization and customer service levels.
- New HVP Finishing Capacity InvestmentsThe company is beginning a new wave of meaningful capital investments to expand HVP finishing capacity in Europe and the U.S. The projects are being added within the existing footprint and are expected to take approximately 18 to 24 months to come online.
- Capital Spending Remains Within the Target RangeNine-month capital expenditures were $125 million, lower than initially planned. Full-year CapEx is now expected to be $215 million-$220 million, within the company’s 6%-8% of revenue corridor, albeit at the low end.
- Balance Sheet and Shareholder ReturnsWest upsized its revolver to $750 million and renewed it for another five years. Year to date, the company paid $47 million in dividends, announced its 34th consecutive year of dividend increases with an 18% increase in the quarterly dividend, and repurchased just over 2.4 million shares for $685 million.
- Raised Full-Year Revenue GuidanceFull-year revenue guidance increased to $3.41 billion-$3.42 billion from $3.345 billion-$3.38 billion. Full-year organic sales growth guidance increased to 11.3%-11.6% from 10%-11%. The outlook includes a 120-basis-point full-year FX benefit and a 160-basis-point reported-growth impact from the SmartDose 3.5 divestiture.
- Raised Full-Year EPS and Margin GuidanceFull-year adjusted EPS guidance increased to $9.38-$9.48 from $8.85-$9.05, representing expected year-over-year growth of 29%-30%. Full-year operating margins are expected to expand by almost 300 basis points.
- Constructive Fourth-Quarter OutlookQ4 revenue guidance is $820 million-$830 million and represents 6%-7% organic revenue growth. Management expects Q4 growth to be driven by double-digit growth in HVP Components.
- Strategic Customer and Continuous-Improvement PrioritiesManagement said West is on the very short list of preferred partners because of its reputation, technical expertise, regulatory expertise, quality, and delivery performance. Priorities include developing more strategic customer relationships, improving demand planning and innovation adoption, and strengthening continuous-improvement efforts through digitization and automation.
- West Vantage Strategy Is ProgressingManagement said West Vantage is progressing as expected, with higher-value-added contracts ramping, a good funnel of opportunities, and continued execution by the team. The company is shifting toward higher-value drug-handling components while rolling off legacy programs.
- Long-Term Biologics and HVP Growth DriversBiologics revenue grew 26% year to date. Management cited record levels of scientific innovation and a record clinical-development pipeline, with an increasing percentage represented by biologics, as continued growth drivers. HVP is expected to grow faster than the overall company, causing its revenue mix to continue rising over time.
- Large-Scale Patient and Customer ImpactWest is on track to deliver over 40 billion highly critical components to customers this year.
- Disciplined M&A ApproachManagement said the initial focus will be on strengthening organic growth. Given West’s financial profile and organic prospects, the bar for M&A is described as incredibly high, with transactions expected to amplify the financial profile and provide value to customers and shareholders.
- Existing Footprint Supports Near-Term DemandManagement said the existing capacity is sufficient to continue supporting demand, with significant labor investments already increasing capacity at several HVP sites. Tech transfers are also being used to level-load facilities and improve utilization of the existing footprint.
DE:WPS Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 2.04- | 1.82 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.962.37 | 1.75 | 35.71% (+0.62) | |
| Jul 23, 2026 | 2026 (Q2) | 1.862.11 | 1.64 | 28.80% (+0.47) | |
| Apr 23, 2026 | 2026 (Q1) | 1.501.90 | 1.29 | 46.90% (+0.61) | |
| Feb 12, 2026 | 2025 (Q4) | 1.641.82 | 1.62 | 12.09% (+0.20) | |
| Oct 23, 2025 | 2025 (Q3) | 1.501.75 | 1.65 | 5.95% (+0.10) | |
| Jul 24, 2025 | 2025 (Q2) | 1.351.64 | 1.36 | 21.05% (+0.29) | |
| Apr 24, 2025 | 2025 (Q1) | 1.091.29 | 1.39 | -7.05% (-0.10) | |
| Feb 13, 2025 | 2024 (Q4) | 1.531.62 | 1.63 | -0.55% (-0.01) | |
| Oct 24, 2024 | 2024 (Q3) | 1.341.65 | 1.93 | -14.35% (-0.28) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.